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ZNF217 is a candidate oncogene with a wide variety of deleterious functions in breast
cancer. Here, we aimed at investigating in a pilot prospective study the association
between ZNF217 mRNA expression levels and the clinical response to neoadjuvant
endocrine therapy (ET) in postmenopausal ER-positive (ER+) breast cancer patients.
Core surgical biopsy samples before treatment initiation and post-treatment were
obtained from 68 patients, and Ki-67 values measured by immunohistochemistry (IHC)
were used to identify responders (n = 59) and non-responders (n = 9) after 4 months of
ET. We report for the first time that high ZNF217 mRNA expression level measured by
RT-qPCR in the initial tumor samples (pre-treatment) is associated with poor response to
neoadjuvant ET. Indeed, the clinical positive response rate in patients with low ZNF217
expression levels was significantly higher than that in those with high ZNF217 expression
levels (P = 0.027). Additionally, a retrospective analysis evaluating ZNF217 expression
levels in primary breast tumor of ER+/HER2−/LN0 breast cancer patients treated with
adjuvant ET enabled the identification of poorer responders prone to earlier relapse
(P = 0.013), while ZNF217 did not retain any prognostic value in the ER+/HER2−/LN0
breast cancer patients who did not receive any treatment. Altogether, these data
suggest that ZNF217 expression might be predictive of clinical response to ET.
Keywords: breast cancer, ZNF217, endocrine therapy, clinical response, predictive biomarker
Abbreviations: ER+, ERα-positive; ERα, estrogen receptor alpha; ET, endocrine therapy; HR, hormone receptor; IHC,
immunohistochemistry; LN0, no invaded lymph nodes; PR, progesterone receptor; RFS, relapse-free survival; RT-qPCR,
real-time quantitative PCR.
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INTRODUCTION
In recent years, studies investigating neoadjuvant therapies have
emerged improving both patient management by providing
a means of performing less extensive surgery and our
understanding of tumor biology and response to treatment (for
review, Charehbili et al., 2014). Neoadjuvant ET is administered
to HR-positive postmenopausal patients, as recommended by
the 15th St. Gallen International Breast Cancer Conference
(Morigi, 2017). The main advantage of such a preoperative
systemic ET is the prospect of downsizing and down-
staging large tumors, thus facilitating breast-conserving surgical
interventions. Despite the use of standard biomarkers, the
heterogeneity of response to therapy still represents a challenge
to clinicians in terms of selecting the most suitable neoadjuvant
therapy. Thus, there is an urgent need to discover predictive
biomarkers capable to identify patients who will respond to
neoadjuvant ET.
We previously described that high expression levels of
ZNF217, a candidate oncogene, are associated with poor
prognosis, shorter RFS in breast cancer (Vendrell et al.,
2012; Bellanger et al., 2017). A functional crosstalk exists
between ZNF217 and ER signaling (Nguyen et al., 2014),
representing a potential mechanism to escape ET. Most
interestingly, high ZNF217 expression levels confer resistance
to ET in ER+ breast cancer cell lines, and ZNF217 expression
silencing is associated with reversion of such resistance
(Nguyen et al., 2014). Furthermore, a decrease in Ki-67 levels
during neoadjuvant ET (considered alone or as part of a
Preoperative Endocrine Prognostic Index) was shown to predict
response to ET (Dowsett et al., 2005, 2007; Ellis et al.,
2011, 2017; Iwamoto et al., 2017). The aim of this pilot
study is to investigate the predictive value of ZNF217 mRNA
levels for response to neoadjuvant ET in patients with ER+
breast cancer.
MATERIALS AND METHODS
Study Design
This was a prospective neoadjuvant ET study on breast
cancers expressing the estrogen receptor (ER+) and having
a clinical size exceeding 2 cm (T2). This study has been
approved by the local ethics committee (Institut du Cancer
de Montpellier, France). Patients were informed that their
data could be used for research; all the patients signed
an informed consent form and the study was conducted
in accordance with the Declaration of Helsinki principles.
A total of 111 patients were treated for 4 months with
neoadjuvant ET (letrozole 2.5 mg/day or tamoxifen 20 mg/day),
before being subjected to resection surgery (see Supplementary
Material). The response to treatment was evaluated by
monitoring the evolution of a biological marker of proliferation
(Ki-67) before (initial tumor) and after 4 months of ET.
Investigation of ZNF217 mRNA expression levels was also
conducted in the initial breast tumor and in the post-treatment
tumor samples.
Sample Collection
Three micro-biopsies were collected per patient: one for
histopathological diagnosis and the other two were frozen in
liquid nitrogen until further use. These tissues were later used
for RNA extraction and ZNF217 mRNA expression analysis,
respecting post-therapeutic medical diagnostic requirements.
Moreover, IHC examination was carried out to assess the statuses
of ER, PR, HER2, and Ki-67. Ki-67 IHC values were measured
pre- and post-treatment for each patient and used to discriminate
between responders and non-responders (Dowsett et al., 2007).
Patients displaying a 1Ki-67 (Ki-67 IHC value post-treatment –
Ki-67 IHC value pre-treatment) ≤0 were designated to be
responders, while patients with1Ki-67>0 were non-responders.
RNA Extraction and Real-Time
Quantitative PCR (RT-qPCR)
Total RNA was extracted from frozen biopsies using
the RNeasy Mini Kit (Qiagen, Hilden, Germany). After
checking RNA quality, 68 tumor samples were deemed
suitable for expression analysis (59 responders and nine non-
responders) (Supplementary Table 1). Reverse-transcription
and RT-qPCR measurements were performed as described in the
Supplementary Material. A P-value of ≤0.05 was considered to
be statistically significant (StatgraphicsTM Software). ROC-AUC
was investigated using the SPSSTM Software.
The Kaplan-Meier Plotter (KMP) Breast
Cancer Cohort
The KMP cohort investigation resulted from a meta-analysis
of gene-expression profiles from 2,978 primary breast cancer
specimens who had not received any therapy before surgery
and with known adjuvant therapy and clinical follow-up
(Gyorffy and Schafer, 2009). The SPSSTM Software was used
to assess the prognostic value of ZNF217 or Ki-67 mRNA
expression (univariate analysis). Data were divided into two
groups with either high or low expression values according to
the median value. Candidate prognostic factors for RFS with
a 0.1 significance level in univariate analysis were entered in a
multivariate Cox model, and a backward selection procedure was
used to determine independent prognostic markers.
RESULTS
ZNF217 mRNA expression levels were not correlated with Ki-
67 values, neither in the initial breast tumor (pre-treatment)
(r = −0.169, P = 0.17), nor in the post-treatment samples
(r = −0.026, P = 0.83), nor with the 1Ki-67 values (r = −0.136,
P = 0.26), thus ruling out that investigating ZNF217 expression
levels was merely a surrogate markers of Ki-67 expression
(Spearman test).
In responders (n = 59) and in non-responders (n = 9), ZNF217
expression was associated with response to neoadjuvant ET,
since ZNF217 mRNA expression levels tended to be significantly
higher (P = 0.05) in the initial breast tumor in patients who did
not respond to neoadjuvant ET (median = 5.98) than those who
did (median = 3.01) (Figure 1A).
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FIGURE 1 | High ZNF217 mRNA expression levels are associated with poor neoadjuvant ET response. (A) Dot plot representing ZNF217 mRNA expression levels in
the initial breast tumors of responders or non-responders. Medians and 95% confidence intervals are shown for each group. (B) Changes in the Ki-67 expression for
patients in the initial tumor and post-treatment tumor according to the mRNA expression levels of ZNF217. Red lines correspond to the non-responders (displaying
increased 1Ki-67). (C) Receiver operating characteristic (ROC) curve for ZNF217 mRNA expression levels. AUC, area under curve.
FIGURE 2 | High ZNF217 mRNA expression levels are associated with earlier relapse for patients treated with ET only. Kaplan-Meier analyses for relapse-free
survival (RFS) are shown for ER+/HER2–/LN0 breast cancer patients (A) treated with adjuvant ET only and (B) who did not receive any treatment.
Fisher’s exact test was used to investigate the association
between the dichotomized clinical response measures and the
ZNF217 molecular marker. The 68 patients were separated in
two groups, based on the median ZNF217 expression value. The
positive clinical response rate in the low ZNF217 expression
level group was significantly higher (P = 0.027) than that in
the high ZNF217 expression level group, with high ZNF217
expression levels being associated with the absence of response
to neoadjuvant ET (Supplementary Table 2).
The ZNF217 low and high expression level groups were
comparable in terms of Ki-67 values in the initial tumor
(pre-treatment) (P = 0.20, data not shown). Changes in Ki-67
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for individual patients before and after neoadjuvant ET response
are shown in Figure 1B. In the ZNF217 low expression levels
group (Wilcoxon signed-rank test, P< 0.00004), only one patient
was ET-resistant (displaying increased Ki-67 level), while 33/34
patients were responders (Figure 1B). In the ZNF217 high
expression level group (Wilcoxon signed-rank test, P < 0.0025),
eight patients displayed an increase in Ki-67 (ET-resistant
patients), whereas 26 patients were responders (Figure 1B).
Although our study is exploratory with a limited sample size
(n = 68) and with limited relapse events (n = 9), we assessed
the predictive power of ZNF217 expression level for response to
ET. The AUC was 0.701 (95% confidence interval: 0.563–0.838,
P = 0.05), which represents a good/moderate discriminatory
accuracy for a model including few events (n = 9) (Figure 1C).
Based on the ROC curve, the discriminating sensitivity and
specificity were 100 and 51%, respectively.
A number of studies have suggested that post-treatment
biomarkers (such as Ki-67 and ER) could have a better prognostic
value than pre-treatment biomarkers, and investigating
biomarkers in post-treatment samples is thus of interest
(Dowsett et al., 2007; Ellis et al., 2008; Chia et al., 2010). In post-
treatment tumor samples, no differences in ZNF217 expression
levels were observed between responders and non-responders
(P = 0.4, Mann-Whitney test, data not shown), suggesting that
assessing ZNF217 expression levels in the initial tumor before ET
is the most informative.
To support our finding, we then hypothesized that if ZNF217
expression retains any predictive value for ET response in
the neoadjuvant setting, then, the biomarker value of ZNF217
would be different between ER+ breast cancer patients treated
with adjuvant ET only and patients who did not received any
treatment. We thus performed a retrospective analysis of gene-
expression array data from 2,978 breast cancer patients (KMP
cohort). In this cohort, we have previously demonstrated that
high levels of ZNF217 mRNA expression levels were strongly
and significantly associated with shorter RFS (P < 10−9, Nguyen
et al., 2014). Strikingly, when considering the ER+/HER2−/LN0
patients, high ZNF217 mRNA levels were predictive of earlier
relapse for patients treated with adjuvant ET only (n = 399,
P = 0.018, univariate analysis), but not for non-treated patients
(n = 639, P = 0.74, univariate analysis) (Figure 2). In ER+/HER2–
/LN0 patients, ZNF217, and Ki-67 mRNA expression levels
were not correlated (r = −0.07, P = 0.14, Spearman test).
Since Ki-67 mRNA levels were almost significantly correlated
with RFS in this cohort (P = 0.094, univariate analysis),
the two factors were entered in a multivariate Cox model,
and both persisted in the model showing that they are
independent biomarkers (P < 0.1). A signature associating
ZNF217 and Ki-67 mRNA levels displayed a prognostic value
with regards to RFS (P = 0.01, univariate analysis). Interestingly,
this signature was identified as the best fit for predicting
clinical outcome of ET-treated patients (likelihood = 741.46),
compared to the models integrating ZNF217 mRNA levels
(likelihood = 746.65, P = 0.023) or Ki-67 mRNA levels
(likelihood = 749.24, P = 0.005) only. Our data support that
ZNF217 is a predictive biomarker for response to ET, and
that, in the ER+/HER2−/LN0 cohort, the signature including
both ZNF217/Ki-67 mRNA levels had the best predictive
value.
DISCUSSION
Short-term pre-operative trials with specific groups of patients
have proven to be highly promising in identifying biomarkers
predictive for the efficacy of targeted anti-cancer therapies
(Marous et al., 2015). Early evidence of endocrine drug
effectiveness can be obtained in the pre-operative (neoadjuvant)
setting by profiling baseline and on-treatment biopsy samples
using the window-of-opportunity. This predictive evidence
acquired during short-term neoadjuvant therapy can help in
identifying individual patients who will potentially benefit from
long-term adjuvant treatment enabling personalized approaches.
Short-term reduction in Ki-67 is predictive of clinical response
to ET (Dowsett et al., 2005, 2007; Ellis et al., 2011, 2017;
Iwamoto et al., 2017). However, controversy remains regarding
the reproducibility of Ki-67 measurements and international
efforts are ongoing to standardize and validate Ki-67 by IHC
(Polley et al., 2015; Rimm et al., 2018). An additional obstacle
derives from intra-tumor heterogeneity of Ki-67 (Focke et al.,
2016). Altogether, there is an urgent need for further biomarkers
that might increase the accuracy of prediction of response
to ET.
In a previous study, proliferation-associated genes, including
cyclins, mini chromosome maintenance genes and mitotic
spindle-associated genes were shown to be predictive of response
to ET after 2 weeks but not before treatment (Turnbull et al.,
2015). A four-gene signature measuring two genes pre-treatment
and two genes after 2 weeks of treatment was shown to
predict response to neoadjuvant ET in ER+ patients (Turnbull
et al., 2015). The genes that predicted response to ET included
two pre-treatment genes associated with immune response and
apoptosis and two genes measured after 2 weeks of treatment,
which were associated with proliferation. Altogether, these
data suggest that transcriptomic changes that develop during
treatment are representative of the drug’s mechanism of action,
suggesting that suppression of proliferation is the main driver of
response.
In the present pilot study, the clinical sample size used is small
and included only nine non-responders. Nevertheless, we found
that ZNF217 expression levels are predictive of neoadjuvant ET
response in ER+ breast cancer. ZNF217 expression levels are
not associated with Ki-67 values, neither in the initial nor in
the treated tumor, ruling out that ZNF217 could only be a
surrogate marker of cell proliferation. Of utmost interest is that
the predictive value of ZNF217 expression levels seems to reside
in the initial tumor and is not the reflection of transcriptional
changes following ET in the treated tumors. This is the first pilot
prospective study conducted in the neoadjuvant setting to relate
ZNF217 expression levels with treatment efficacy, thus suggesting
that aside from its prognostic value in luminal breast cancers
(Vendrell et al., 2012; Nguyen et al., 2014), ZNF217 expression
may also be predictive of response to ET. In this exploratory
study, it is difficult to estimate the accuracy of ZNF217 mRNA
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levels for predicting response to ET, due to the low numbers
of non-responders (9 out of 68). However, while obtained in a
small cohort, our preliminary data are encouraging and need to
be extended to a larger cohort for validation.
Interestingly, evaluating ZNF217 expression levels in the
primary breast tumor of ER+/HER2−/LN0 breast cancer
patients treated by adjuvant ET led to the identification
of poorer responders prone to earlier relapse, while in
ER+/HER2−/LN0 breast cancer patients who did not receive
any treatment the association between ZNF217 expression
and RFS was not significant. Previous studies reported multi-
gene genomic assays predicting response to neoadjuvant ET
(Turnbull et al., 2015; Iwata et al., 2018), and we speculate
that these coupling with the ZNF217 biomarker might improve
their predictive performance. Indeed, we herein demonstrated
in the ER+/HER2–/LN0 cohort that combining ZNF217 and
Ki-67 expression levels was more performant at predicting
relapse under ET, than each of these biomarkers taken
individually.
Altogether, these data support the idea that in the luminal
breast cancer subclass, ZNF217 expression levels relate to ET
response and provide a novel candidate biomarker. Finally,
there are several ongoing trials investigating the combination
of ET and other targeted therapies to prevent/reverse endocrine
resistance. The PI3K/mTOR pathway, CDK4/6, HDAC, and
immune checkpoints are the most promising and widely
investigated targets (Rugo et al., 2016). Further studies are
needed to delineate whether the ER+/ZNF217high breast
cancer subpopulation might benefit from combining ET with
another therapy.
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